^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    temozolomide

    i
    Company:
    Generic mfg.
    Drug class:
    DNA synthesis inhibitor
    Related drugs:
    Apply
    Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease (NCT06023641)
    Phase 1/2
    St. Jude Children's Research Hospital
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    03/13/2024
    Primary completion :
    10/01/2034
    Completion :
    10/01/2037
    TP53 • FOXO1 • MYOD1
    |
    TP53 mutation
    |
    temozolomide • cyclophosphamide • vincristine • vinorelbine tartrate • dactinomycin • Onivyde (nanoliposomal irinotecan) • Navelbine oral (vinorelbine tartrate oral) • Neupogen (filgrastim)
    Carmustine Wafer in Combination With Retifanlimab and Radiation With/Without Temozolomide in Subjects With Glioblastoma (NCT05083754)
    Phase 1
    Sidney Kimmel Comprehensive Cancer Center at Jo...
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    08/31/2022
    Primary completion :
    01/01/2026
    Completion :
    01/01/2027
    PD-L1 • MSI • CD8 • PD-1 • CD4 • ICOS
    |
    temozolomide • carmustine • Zynyz (retifanlimab-dlwr)
    Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma (NCT04901702)
    Phase 1/2
    St. Jude Children's Research Hospital
    Active, not recruiting
    Last update posted :
    02/24/2025
    Initiation :
    06/09/2021
    Primary completion :
    12/31/2025
    Completion :
    12/31/2025
    EWSR1 • FLI1
    |
    temozolomide • Talzenna (talazoparib) • Onivyde (nanoliposomal irinotecan)
    Study of Olutasidenib and Temozolomide in HGG (NCT06161974)
    Phase 2
    Rigel Pharmaceuticals
    Recruiting
    Last update posted :
    02/21/2025
    Initiation :
    03/01/2025
    Primary completion :
    06/01/2029
    Completion :
    06/01/2035
    IDH1
    |
    IDH1 mutation
    |
    temozolomide • Rezlidhia (olutasidenib)
    Testing the Addition of an Anticancer Drug, Olaparib, to the Usual Chemotherapy (Temozolomide) for Advanced Neuroendocrine Cancer (A021804) (NCT04394858)
    Phase 2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/20/2025
    Initiation :
    03/17/2021
    Primary completion :
    02/28/2026
    Completion :
    02/28/2026
    MGMT • CD4
    |
    Lynparza (olaparib) • temozolomide
    Vincristine and Temozolomide in Combination With PEN-866 for Adolescents and Young Adults With Relapsed or Refractory Solid Tumors (NCT04890093)
    Phase 1/2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/20/2025
    Initiation :
    10/31/2024
    Primary completion :
    02/28/2026
    Completion :
    12/31/2026
    UGT1A1
    |
    UGT1A1*28 • UGT1A1*1*1
    |
    temozolomide • vincristine • locnartecan (PEN-866)
    DB107-RRV, DB107-FC, and Radiation Therapy with or Without Temozolomide (TMZ) for High Grade Glioma (NCT06504381)
    Phase 1/2
    University of California, San Francisco
    Recruiting
    Last update posted :
    02/19/2025
    Initiation :
    01/08/2025
    Primary completion :
    01/31/2028
    Completion :
    01/31/2042
    MGMT
    |
    temozolomide • vocimagene amiretrorepvec/extended release flucytosine (DB107)
    Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies (CERTIS1) (NCT05417594)
    Phase 1/2
    AstraZeneca
    Recruiting
    Last update posted :
    02/19/2025
    Initiation :
    06/24/2022
    Primary completion :
    08/28/2026
    Completion :
    08/28/2026
    HER-2 • BRCA1 • BRCA2 • IDH1 • IDH2 • HRD • BRCA • RAD51C • RAD51D
    |
    HER-2 negative • PALB2 mutation • RAD51C mutation • RAD51D mutation
    |
    temozolomide • Enhertu (fam-trastuzumab deruxtecan-nxki) • Datroway (datopotamab deruxtecan) • AZD9574
    Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma (NCT06172296)
    Phase 3
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/19/2025
    Initiation :
    04/19/2024
    Primary completion :
    12/31/2029
    Completion :
    12/31/2029
    ALK • TERT • MYCN
    |
    cisplatin • carboplatin • temozolomide • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • irinotecan • vincristine • daunorubicin • topotecan • melphalan • thiotepa • Qarziba (dinutuximab beta) • Unituxin (dinutuximab) • dexrazoxane
    Study of Efficacy and Safety of Ribociclib (LEE011) in Combination With Topotecan and Temozolomide (TOTEM) in Pediatric Patients With Relapsed or Refractory Neuroblastoma and Other Solid Tumors (NCT05429502)
    Phase 1/2
    Novartis Pharmaceuticals
    Recruiting
    Last update posted :
    02/17/2025
    Initiation :
    12/27/2022
    Primary completion :
    10/15/2027
    Completion :
    01/28/2028
    MYCN • SMARCB1
    |
    IDH wild-type
    |
    temozolomide • Kisqali (ribociclib) • topotecan
    A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors (ST101-101) (NCT04478279)
    Phase 1/2
    Sapience Therapeutics
    Active, not recruiting
    Last update posted :
    02/17/2025
    Initiation :
    07/01/2020
    Primary completion :
    12/01/2025
    Completion :
    12/01/2025
    BRAF
    |
    HR positive • BRAF mutation
    |
    temozolomide • Xtandi (enzalutamide) • abiraterone acetate • lucicebtide (ST101)
    VITAS: Atezolizumab in Combination with Chemotherapy for Pediatric Relapsed/refractory Solid Tumors (NCT04796012)
    Phase 1/2
    University of Texas Southwestern Medical Center
    Recruiting
    Last update posted :
    02/13/2025
    Initiation :
    04/18/2023
    Primary completion :
    01/01/2027
    Completion :
    01/01/2027
    PD-L1
    |
    Tecentriq (atezolizumab) • temozolomide • irinotecan • vincristine
    Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma (NCT03794349)
    Phase 2
    Children's Oncology Group
    Active, not recruiting
    Last update posted :
    02/13/2025
    Initiation :
    07/08/2019
    Primary completion :
    03/31/2025
    Completion :
    03/31/2025
    IFNG • IL6 • CD276 • TNFA
    |
    temozolomide • irinotecan • Qarziba (dinutuximab beta) • Unituxin (dinutuximab) • Leukine (sargramostim)
    Safety & Efficacy of DC Vaccine and TMZ for the Treatment of Newly-diagnosed Glioblastoma After Surgery (NCT04968366)
    Phase 1
    Beijing Tiantan Hospital
    Active, not recruiting
    Last update posted :
    02/11/2025
    Initiation :
    07/30/2021
    Primary completion :
    04/30/2024
    Completion :
    12/31/2028
    IDH1 • IDH2
    |
    IDH wild-type
    |
    temozolomide
    Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma (NRG-BN007) (NCT04396860)
    Phase 2/3
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/10/2025
    Initiation :
    09/01/2020
    Primary completion :
    04/13/2023
    Completion :
    03/11/2025
    PD-L1 • TMB • IDH1 • MGMT
    |
    PD-L1 expression • MGMT promoter methylation • IDH1 R132
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • temozolomide • CS1002 (ipilimumab biosimilar) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar)
    Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment (NCT05432804)
    Phase 1/2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/06/2025
    Initiation :
    03/20/2023
    Primary completion :
    06/30/2026
    Completion :
    06/30/2026
    MGMT
    |
    IDH wild-type
    |
    temozolomide • Xpovio (selinexor)
    Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) (NCI-MATCH) (NCT02465060)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/06/2025
    Initiation :
    08/17/2015
    Primary completion :
    12/31/2025
    Completion :
    12/31/2025
    MSI • CD4
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Avastin (bevacizumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • Mekinist (trametinib) • cisplatin • Xalkori (crizotinib) • Tagrisso (osimertinib) • Tecentriq (atezolizumab) • Gilotrif (afatinib) • Yervoy (ipilimumab) • Ibrance (palbociclib) • dasatinib • Tafinlar (dabrafenib) • carboplatin • Imfinzi (durvalumab) • Vitrakvi (larotrectinib) • Imbruvica (ibrutinib) • gemcitabine • paclitaxel • Rituxan (rituximab) • docetaxel • 5-fluorouracil • sunitinib • everolimus • Vectibix (panitumumab) • temozolomide • Koselugo (selumetinib) • Perjeta (pertuzumab) • cytarabine • Kadcyla (ado-trastuzumab emtansine) • bortezomib • doxorubicin hydrochloride • Talzenna (talazoparib) • capecitabine • Piqray (alpelisib) • Xtandi (enzalutamide) • azacitidine • Cabometyx (cabozantinib tablet) • Balversa (erdafitinib) • Gazyva (obinutuzumab) • Mektovi (binimetinib) • albumin-bound paclitaxel • cyclophosphamide • Imjudo (tremelimumab-actl) • Cyramza (ramucirumab) • pemetrexed • fulvestrant • oxaliplatin • adavosertib (AZD1775) • etoposide IV • irinotecan • Halaven (eribulin mesylate) • Xpovio (selinexor) • Conmana (icotinib) • Pemazyre (pemigatinib) • Truqap (capivasertib) • methotrexate • Zarnestra (tipifarnib) • Aliqopa (copanlisib) • fexagratinib (ABSK091) • Ninlaro (ixazomib) • pegylated liposomal doxorubicin • epirubicin • sapanisertib (CB-228) • ipatasertib (RG7440) • Caprelsa (vandetanib) • vincristine • vinorelbine tartrate • Cometriq (cabozantinib capsule) • Tabrecta (capmatinib) • spartalizumab (PDR001) • taselisib (GDC-0032) • daunorubicin • omipalisib (GSK2126458) • ulixertinib (BVD-523) • mitoxantrone • Erivedge (vismodegib) • carmustine • bicalutamide • leucovorin calcium • bendamustine • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Zepzelca (lurbinectedin) • mitomycin • Jingzhuda (entinostat) • Recentin (cediranib) • Trazimera (trastuzumab-qyyp) • melphalan • GSK2636771 • Zirabev (bevacizumab-bvzr) • defactinib (VS-6063) • goserelin acetate • Zynyz (retifanlimab-dlwr) • fludarabine IV • Ostarine (enobosarm) • avadomide (CC-122) • vistusertib (AZD2014) • Myocet (non-pegylated liposomal doxorubicin) • mesna • vinblastine • Xofigo (radium Ra-223 dichloride) • lorvotuzumab mertansine (IMGN901) • Ampligen (rintatolimod) • E6201 • Fujovee (abivertinib) • Provenge (sipuleucel-T) • TQB2440 (pertuzumab biosimilar) • relatlimab (BMS-986016) • ABP 206 (nivolumab biosimilar) • Airuituo (bevacizumab biosimilar) • BCD-178 (pertuzumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • CC-90002 • EG1206A (pertuzumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • ImmuniCell (autologous γδ T lymphocytes) • Leukine (sargramostim) • Vasforda (bevacizumab biosimilar) • celecoxib oral • cyclophosphamide intravenous • dexamethasone injection • ieramilimab (LAG525) • levoleucovorin calcium • methotrexate IV • sapitinib (AZD8931)
    Surgical Pembro +/- Olaparib W TMZ for RGBM (NCT05463848)
    Phase 2
    L. Nicolas Gonzalez Castro, MD, PhD
    Recruiting
    Last update posted :
    02/06/2025
    Initiation :
    10/21/2022
    Primary completion :
    08/01/2025
    Completion :
    04/01/2026
    EGFR • TERT
    |
    EGFR mutation • EGFR amplification • IDH wild-type
    |
    Keytruda (pembrolizumab) • Lynparza (olaparib) • temozolomide
    Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations (ACNS1721) (NCT03581292)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/04/2025
    Initiation :
    11/06/2018
    Primary completion :
    03/31/2023
    Completion :
    10/16/2025
    BRAF
    |
    IDH wild-type
    |
    temozolomide • veliparib (ABT-888)
    Pembrolizumab, Olaparib, and Temozolomide for People with Glioma (NCT05188508)
    Phase 2
    Memorial Sloan Kettering Cancer Center
    Recruiting
    Last update posted :
    02/03/2025
    Initiation :
    01/14/2022
    Primary completion :
    01/01/2026
    Completion :
    01/01/2026
    EGFR • BRCA1 • BRCA2 • HRD • CDKN2A • FGFR • CDK12 • CDKN2B • CHEK2 • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • BARD1 • RAD54L • FANCL • PPP2R2A
    |
    CDKN2A deletion • BRIP1 mutation • RAD51C mutation • RAD51B mutation • BARD1 mutation • IDH wild-type
    |
    Keytruda (pembrolizumab) • Lynparza (olaparib) • temozolomide
    Imaging and Biological Markers for Prediction and Identification of Glioblastoma Pseudoprogression: a Prospective Study. (NCT06113705)
    Phase N/A
    Istituto Clinico Humanitas
    Recruiting
    Last update posted :
    01/31/2025
    Initiation :
    11/01/2023
    Primary completion :
    12/31/2026
    Completion :
    12/31/2026
    IDH1 • IDH2 • MGMT
    |
    IDH wild-type
    |
    temozolomide
    Study on Tailored Treatment in Elderly Patients With Newly Diagnosed Primary Lymphoma of Central Nervous System (FIORELLA) (NCT03495960)
    Phase 2
    International Extranodal Lymphoma Study Group (...
    Completed
    Last update posted :
    01/30/2025
    Initiation :
    06/15/2019
    Primary completion :
    12/12/2024
    Completion :
    12/12/2024
    CD20
    |
    Rituxan (rituximab) • lenalidomide • temozolomide • Matulane (procarbazine hydrochloride)
    Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE (NCT04919226)
    Phase 3
    ITM Solucin GmbH
    Recruiting
    Last update posted :
    01/29/2025
    Initiation :
    12/21/2021
    Primary completion :
    06/01/2027
    Completion :
    09/01/2027
    SSTR
    |
    SSTR positive
    |
    5-fluorouracil • everolimus • temozolomide • capecitabine • oxaliplatin • leucovorin calcium • Solucin (177Lu-edotreotide)
    5G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours (NCT06630260)
    Phase 1/2
    Institute of Cancer Research, United Kingdom
    Recruiting
    Last update posted :
    01/22/2025
    Initiation :
    11/15/2024
    Primary completion :
    09/30/2029
    Completion :
    09/30/2030
    BRAF
    |
    temozolomide • avutometinib (VS-6766) • defactinib (VS-6063)
    Regorafenib With Temozolomide With or Without RT in MGMT-Methylated, IDH Wild-type GBM Patients (REGOMA-2) (NCT06095375)
    Phase 1
    Istituto Oncologico Veneto IRCCS
    Active, not recruiting
    Last update posted :
    12/24/2024
    Initiation :
    07/04/2022
    Primary completion :
    10/09/2024
    Completion :
    12/01/2025
    IDH1
    |
    IDH1 R132
    |
    temozolomide • Stivarga (regorafenib)
    Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion (NCT06739395)
    Phase 2
    Tianjin Medical University Second Hospital
    Recruiting
    Last update posted :
    12/18/2024
    Initiation :
    11/01/2024
    Primary completion :
    12/31/2026
    Completion :
    05/01/2027
    BRAF
    |
    Lynparza (olaparib) • Mekinist (trametinib) • Ibrance (palbociclib) • Tafinlar (dabrafenib) • Focus V (anlotinib) • temozolomide • Lenvima (lenvatinib) • Piqray (alpelisib) • pazopanib • Epidaza (chidamide) • Trodelvy (sacituzumab govitecan-hziy) • bozitinib (APL-101)
    Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM (NCT02287428)
    Phase 1
    Dana-Farber Cancer Institute
    Recruiting
    Last update posted :
    12/05/2024
    Initiation :
    11/01/2014
    Primary completion :
    06/01/2025
    Completion :
    06/01/2026
    MGMT
    |
    MGMT promoter methylation
    |
    Keytruda (pembrolizumab) • temozolomide • Hiltonol (poly-ICLC) • Neo Vax (NEO-PV-01)
    New Adjuvant Vaccine in Glioblastoma, a Phase 1/2a Study (NAVIG-1) (NCT06622434)
    Phase 1/2
    Assistance Publique - Hôpitaux de Paris
    Recruiting
    Last update posted :
    12/04/2024
    Initiation :
    11/08/2024
    Primary completion :
    05/08/2027
    Completion :
    05/08/2027
    PTPRZ1
    |
    temozolomide
    INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT) (NCT02977780)
    Phase 2
    Patrick Wen, MD
    Recruiting
    Last update posted :
    10/17/2024
    Initiation :
    02/09/2017
    Primary completion :
    02/01/2027
    Completion :
    04/30/2027
    IDH1
    |
    IDH1 R132
    |
    temozolomide • Nerlynx (neratinib) • Verzenio (abemaciclib) • CC-115 • QBS72S
    A Study of Selinexor in Combination With Temozolomide and Anti-PD-1 Antibody in Patients With Relapsed/Refractory Primary Central Nervous System Lymphoma (NCT06556199)
    Phase 1/2
    Second Affiliated Hospital, School of Medicine,...
    Recruiting
    Last update posted :
    08/15/2024
    Initiation :
    08/31/2024
    Primary completion :
    08/31/2026
    Completion :
    08/31/2028
    IFNG • IL6 • TNFA • IL2 • IL10
    |
    temozolomide • Xpovio (selinexor)
    ARISTOCRAT: Blinded Trial of Temozolomide +/- Cannabinoids (NCT05629702)
    Phase 2
    University of Birmingham
    Recruiting
    Last update posted :
    06/17/2024
    Initiation :
    02/03/2023
    Primary completion :
    02/01/2026
    Completion :
    02/01/2027
    MGMT
    |
    IDH wild-type
    |
    temozolomide • Sativex (nabiximols)
    Cabozantinib in High Grade Neuroendocrine Neoplasms (NCT04412629)
    Phase 2
    Washington University School of Medicine
    Recruiting
    Last update posted :
    06/14/2024
    Initiation :
    11/24/2020
    Primary completion :
    07/31/2025
    Completion :
    03/31/2026
    SYP
    |
    temozolomide • Cabometyx (cabozantinib tablet)
    Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM (SONOBIRD) (NCT05902169)
    Phase 3
    CarThera
    Recruiting
    Last update posted :
    06/12/2024
    Initiation :
    01/29/2024
    Primary completion :
    01/28/2028
    Completion :
    06/30/2028
    BRAF • IDH1
    |
    BRAF mutation • IDH1 R132H • IDH1 R132
    |
    carboplatin • temozolomide • lomustine
    Telaglenastat With Radiation Therapy and Temozolomide in Treating Patients With IDH-Mutated Diffuse Astrocytoma or Anaplastic Astrocytoma (NCI-2018-00876) (NCT03528642)
    Phase 1
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    06/07/2024
    Initiation :
    05/01/2019
    Primary completion :
    12/05/2024
    Completion :
    12/05/2024
    IDH1 • IDH2
    |
    IDH1 mutation • IDH2 mutation
    |
    temozolomide • telaglenastat (CB-839)
    Ipilimumab + Temozolomide in Metastatic Melanoma (NCT01119508)
    Phase 2
    M.D. Anderson Cancer Center
    Completed
    Last update posted :
    06/06/2024
    Initiation :
    05/01/2010
    Primary completion :
    08/01/2016
    Completion :
    08/01/2016
    IL2
    |
    Yervoy (ipilimumab) • temozolomide
    A Phase 2b Clinical Study With a Combination Immunotherapy in Newly Diagnosed Patients With Glioblastoma (NCT04485949)
    Phase 2
    Imvax
    Active, not recruiting
    Last update posted :
    05/31/2024
    Initiation :
    03/20/2023
    Primary completion :
    01/01/2025
    Completion :
    07/01/2027
    MGMT
    |
    temozolomide • IGV-001
    LAM561 With RT and TMZ for Adults With Glioblastoma (CLINGLIO) (NCT04250922)
    Phase 2/3
    Laminar Pharmaceuticals
    Active, not recruiting
    Last update posted :
    05/31/2024
    Initiation :
    12/01/2019
    Primary completion :
    10/15/2024
    Completion :
    05/30/2025
    IDH1 • MGMT
    |
    MGMT promoter methylation • IDH wild-type
    |
    temozolomide • Minerval (idroxioleic acid)
    An Investigational Immuno-therapy Study of Temozolomide Plus Radiation Therapy With Nivolumab or Placebo, for Newly Diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer) (CheckMate 548) (NCT02667587)
    Phase 3
    Bristol-Myers Squibb
    Completed
    Last update posted :
    05/29/2024
    Initiation :
    05/09/2016
    Primary completion :
    12/22/2020
    Completion :
    04/09/2024
    MGMT
    |
    Opdivo (nivolumab) • temozolomide
    Comparing Capecitabine and Temozolomide in Combination to Lutetium Lu 177 Dotatate in Patients With Advanced Pancreatic Neuroendocrine Tumors (NCT05247905)
    Phase 2
    Alliance for Clinical Trials in Oncology
    Recruiting
    Last update posted :
    05/23/2024
    Initiation :
    03/16/2022
    Primary completion :
    03/31/2028
    Completion :
    10/01/2033
    SSTR
    |
    temozolomide • capecitabine • Lutathera (lutetium Lu 177 dotatate)
    Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma (NCT00887146)
    Phase 3
    Alliance for Clinical Trials in Oncology
    Recruiting
    Last update posted :
    05/23/2024
    Initiation :
    09/01/2009
    Primary completion :
    10/01/2025
    Completion :
    10/01/2025
    IDH1 • IDH2
    |
    temozolomide • vincristine • Matulane (procarbazine hydrochloride)